阿賓登健康交易下跌 10.0%

Abingdon Health Plc（倫敦證券交易所代碼：ABDX – 獲取免費報告）的股價週四下跌 6.7%。該股最低交易價格為 GBX 9.53（0.12 美元），最後交易價格為 GBX 10.03（0.13 美元）。

LONDON (MarketWatch) — Shares of Abingdon Health Plc (ABDX) fell sharply Thursday after the rapid-test maker said it’s in talks with potential partners for a licensing deal for its Covid-19 lateral flow test in the U.S.

倫敦（MarketWatch）—週四，Abingdon Health Plc (ABDX) 股價大幅下跌，此前這家快速檢測製造商表示正在與潛在合作夥伴就其在美國的 Covid-19 側向層析檢測的許可協議進行談判

Abingdon shares were recently down 10%, among the worst performers in the FTSE All-Share Index (FTAS) , which was up 0.3%. The stock traded as low as 9.53 pence ($0.12) and last traded at 10.03 pence ($0.13).

Abingdon 股價最近下跌 10%，是富時全股指數 (FTAS) 中表現最差的股票之一，該指數上漲了 0.3%。該股交易價格低至 9.53 便士（0.12 美元），最新交易價格為 10.03 便士（0.13 美元）。

The company said it’s had “positive initial discussions” with potential partners, and that it now plans to begin formal negotiations for a licensing deal for the test in the U.S.

該公司表示，已與潛在合作夥伴進行了“積極的初步討論”，現在計劃開始就在美國進行測試的許可協議進行正式談判

The talks come after Abingdon said in March that it had received emergency-use authorization from the Food and Drug Administration for its Covid-19 lateral flow test, which can detect the virus in 15 minutes. The test is already available in the U.K.

在會談之前，Abingdon 在 3 月表示，其 Covid-19 側流檢測已獲得美國食品和藥物管理局的緊急使用授權，該檢測可在 15 分鐘內檢測出病毒。該測試已在英國推出

Abingdon said Thursday that it also continues to be in discussions with potential partners for licensing deals in other territories.

阿賓登週四表示，它還在繼續與潛在合作夥伴討論其他地區的授權交易。

The company added that it’s also working on developing a new lateral flow test for the Omicron variant of Covid-19, which is expected to be available in the second half of 2022.

該公司補充說，它還在致力於為 Covid-19 的 Omicron 變體開發一種新的側向層析測試，預計將於 2022 年下半年推出。

Abingdon shares have now lost 86% of their value over the past year, as demand for Covid-19 tests has waned and the company has struggled to find new licensing partners for its products.

由於對 Covid-19 測試的需求減弱以及該公司一直在努力為其產品尋找新的授權合作夥伴，Abingdon 的股價在過去一年中已經損失了 86%。